Human Models of Selective Insulin Resistance: Alpelisib, Part I

NCT06354088 · clinicaltrials.gov ↗

PHASE1

Phase

RECRUITING

Status

32

Enrollment

OTHER

Sponsor class

Conditions

Insulin Resistance
Prediabetic State
Overweight and Obesity
Non-Alcoholic Fatty Liver Disease

Interventions

DRUG: Alpelisib 300 mg
DRUG: Placebo
DRUG: [1-13C] sodium acetate
DRUG: [6,6-2H2] D-glucose
DIETARY_SUPPLEMENT: Nestlé BOOST Plus

Sponsor

Columbia University

Collaborators

[object Object]
[object Object]
[object Object]